A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 – New data further reinforce Ocrevus (ocrelizumab) as a highly effective treatment ...

March is Multiple Sclerosis Awareness Month, making it a good time to discuss and spread awareness about this degenerative neurological condition that affects about 1 million adults in the US. We ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus ® (ocrelizumab) data and continued research into ...

What clinical endpoints are most influential when determining access for multiple sclerosis (MS) treatments? Snow: Plans are really looking for “hard clinical outcomes” and outcomes that can be ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

Abundance of severe gum disease like periodontitis may worsen disability for people with multiple sclerosis (MS), a chronic ...

Genentech, a member of the Roche Group, today announced that new multiple sclerosis and neuromyelitis optica spectrum disorder data will be presented at MSVirtual2020, the 8th Joint Americas Committee ...